DA-2811
/ Dong-A
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
November 21, 2025
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
(clinicaltrials.gov)
- P2 | N=288 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.
New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 18, 2025
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control
(clinicaltrials.gov)
- P4 | N=231 | Completed | Sponsor: Dong-A ST Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Mar 2025 | Trial primary completion date: Dec 2024 ➔ Mar 2025
Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
February 16, 2024
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
(clinicaltrials.gov)
- P4 | N=232 | Recruiting | Sponsor: Dong-A ST Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Dec 2024
Enrollment open • Monotherapy • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 29, 2023
A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects.
(PubMed, Drug Des Devel Ther)
- "Dapagliflozin formate (DAP-FOR, DA-2811), an ester prodrug of dapagliflozin, was developed to improve the stability and pharmaceutical manufacturing process of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor. The safety profiles were also similar between the two drugs. These results suggest that DAP-FOR can be used as an alternative to DAP-PDH."
Clinical • PK/PD data
February 24, 2023
Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
(clinicaltrials.gov)
- P4 | N=232 | Not yet recruiting | Sponsor: Dong-A ST Co., Ltd.
Monotherapy • New P4 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
June 06, 2022
Pharmacokinetics and Safety/Tolerability Profiles of DA-2811 in Healthy Subjects (DA-2811)
(clinicaltrials.gov)
- P1 | N=30 | Completed | Sponsor: Dong-A ST Co., Ltd. | Recruiting ➔ Completed
Trial completion
1 to 6
Of
6
Go to page
1